| Grant ID | DP200034 |
| Awarded On | May 20, 2020 |
| Title | CARGo: a CAR-T cell program targeting HLA-G - a novel immune checkpoint and tumor specific antigen for advanced clear cell renal and ovarian carcinomas |
| Program | Product Development Research |
| Award Mechanism | Company Relocation |
| Institution/Organization | Invectys USA Inc |
| Principal Investigator/Program Director | Qi Yang |
| Cancer Sites | Kidney and Renal Pelvis, Ovary |
| Contracted Amount | $14,196,990 |
| Lay Summary |
Invectys S.A. is a French biopharmaceutical company developing innovative anti-cancer products in immunotherapy based on leading technology from the Institut Pasteur in Paris. The Company is applying for a CPRIT relocation grant to advance its novel CAR-T platform to be able to conduct early stage clinical studies in Texas. Invectys research is focused on the HLA-G molecule, a powerful modulator of the human immune system. It is the only cancer immunotherapy company focused on HLA-G: a highly significant and novel approach. HLA-G protects the fetus from the mother's immune system. However, in cancer tumors, cells are selected that express HLA-G to protect the tumor from attacks of the immune... |